Complementary in-vitro experiments have corroborated its pro-tumorigenic impact in lung adenocarcinoma, while high-throughput drug profiling has nominated small-molecule activators of MDH1 for potential therapeutic exploitation. Here, MDH1 is linked to lung adenocarcinoma.